The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [1] The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials
    Guo, Chongzhen
    Yan, Chengda
    Qu, Lianyue
    Du, Rongrong
    Lin, Jianyang
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (02) : 285 - 311
  • [2] Does the age affect the efficacy of angiogenesis inhibitors in ovarian cancer? A meta-analysis of randomized controlled trials
    Miao, H.
    Miao, C-X
    Han, J.
    Li, N.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (13) : 3047 - 3053
  • [3] Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials
    Li, Xuyuan
    Zhu, Sujuan
    Hong, Chaoqun
    Cai, Haoquan
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (03) : 555 - 562
  • [4] Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials
    Fu, Xue-Lei
    Feng, Li-Ping
    Yu, Hai-Rong
    Du, Lin
    Song, Yi-Ping
    Chen, Hong-Lin
    MELANOMA RESEARCH, 2022, 32 (03) : 159 - 165
  • [5] The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta-analysis
    Zhang, Chunmei
    Zhao, Wancheng
    JOURNAL OF OVARIAN RESEARCH, 2022, 15 (01)
  • [6] Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials
    Wang, Haihong
    Xu, Tie
    Zheng, Lifen
    Li, Guiling
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (05) : 903 - 914
  • [7] Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials
    Liang, X. -J.
    Shen, J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (12) : 2701 - 2709
  • [8] Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis
    Simion, Laurentiu
    Rotaru, Vlad
    Cirimbei, Ciprian
    Stefan, Daniela-Cristina
    Gherghe, Mirela
    Ionescu, Sinziana
    Tanase, Bogdan Cosmin
    Luca, Dan Cristian
    Gales, Laurentia Nicoleta
    Chitoran, Elena
    DIAGNOSTICS, 2023, 13 (06)
  • [9] The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis
    Chunmei Zhang
    Wancheng Zhao
    Journal of Ovarian Research, 15
  • [10] The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials
    Zhang, Jian
    Liu, Jie
    Chen, Huiguo
    Wu, Weibin
    Li, Xiaojun
    Wu, Yonghui
    Zhang, Kai
    Gu, Lijia
    ONCOTARGETS AND THERAPY, 2015, 8 : 2375 - 2382
12345